Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab

NCT01025232 is registered in ClinicalTrials.gov with David M. Brown, M.D. as lead sponsor.

NCT NCT01025232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01025232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab
Lead sponsor
David M. Brown, M.D.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2009
Completion date
January 31, 2013
Enrollment
88 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, choroidal neovascular membrane, macular degeneration, subfoveal neovascular age-related macular degeneration, wet age-related macular degeneration